Document is current
Any future updates will be listed below
-
Authors
Kerr, Nathan R.
Dashtmian, Anna R.
Darvishi, Fereshteh B.
Brennan, Charles D.
Ayyagari, Sindhuja N.
Moore, Peter J.
Viteri, Jose A.
Wang, Meifang
Rich, Mark M.
Clark, Brian C.
David Arnold, W. https://orcid.org/0000-0001-9889-7036
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG078129)
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 7 January 2025
First Online: 17 January 2025
Declarations
:
: In the past 5-years, Dr. Clark has received grants from the NIH, NMD Pharma, OsteoDx Inc, and Myolex. He also reports serving as a co-founder and chief of aging research at OsteoDx Inc outside the submitted work. Dr. Arnold has received grant funding from NMD Pharma, Avidity Biosciences, consulting fees from Avidity Biosciences, NMD Pharma, Dyne Therapeutics, Genentech, Design Therapeutics, Catalyst Pharmaceuticals, and Insmed regarding therapeutic development for Duchenne Muscular Dystrophy, Myotonic Dystrophy type 1, and Spinal Muscular Atrophy.
: The authors have no conflict of interest to report.
